メチシリン耐性黄色ブドウ球菌（MRSA）市場：ヨーロッパ主要国の治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology
3.1.1 MRSA Strains
3.1.2 VISA Strains
3.1.3 VRSA Strains
3.2 Pathophysiology
3.2.1 Infection Sites
3.2.2 Expression of Virulence Factors
3.2.3 Mechanisms of Antibiotic Resistance
3.2.4 Biofilm Formation
3.3 Symptoms
3.4 Prognosis
3.4.1 Skin and Soft Tissue Infections
3.4.2 Pneumonia
3.4.3 Bacteremia
3.4.4 Chronic MRSA Infection
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines
4.1.3 Clinical Practice
4.2 5EU
4.2.1 Forecast
4.2.2 Key Events
4.2.3 Drivers and Barriers
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles – Glycopeptides and Lipoglycopeptides
5.2.1 Vancomycin
5.2.2 Dalvance (dalbavancin)
5.2.3 Orbactiv (oritavancin)
5.2.4 Vibativ (telavancin)
5.2.5 Targocid (teicoplanin)
5.3 Product Profiles – Lipopeptides
5.3.1 Cubicin (daptomycin)
5.4 Product Profiles – Oxazolidinones
5.4.1 Zyvox (linezolid)
5.4.2 Sivextro (tedizolid phosphate)
5.5 Product Profiles – Cephalosporins
5.5.1 Teflaro (ceftaroline fosamil)
5.5.2 Zevtera (ceftobiprole medocaril)
5.6 Product Profiles – Glycylcyclines
5.6.1 Tygacil (tigecycline)
5.7 Other Antimicrobial Agents
6 Unmet Need and Opportunity
6.1 Overview
6.2 Drugs with Demonstrated Efficacy in Difficult-to-Treat Patient Populations
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Expand Breadth of Clinical Data Outside of Skin Infections
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Physician Education
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Antibiotics with More Convenient Formulations and Dosing Schedules
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Innovative Approaches to Clinical Trial Design
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Drugs with Novel Mechanisms of Action
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 More Affordable Therapies
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Late-Stage Clinical Development
7.2.1 Delafloxacin (RX-3341)
7.2.2 Solithromycin (CEM-101)
7.2.3 Omadacycline (PTK-0796)
7.2.4 KRP-AM1977X
7.2.5 Taksta (fusidic acid, oral tablets)
7.2.6 Lefamulin (BC-3781)
7.2.7 Debio1450 (Debio1452 prodrug)
7.2.8 Brilacidin
7.3 Other Promising Products in Clinical Development
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Hospitalized MRSA Patients
9.4.2 Percentage of Drug-Treated MRSA Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch, Label Expansion, and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research – KOLs Interviewed for This Report
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Author and Therapy Area Director
9.7.2 Author
9.7.3 Epidemiologist
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer